Moving faster than planned, AI drug developer Accipiter Bio quietly tops up seed round with $10.5M
$10.5M. Accipiter Bio's seed top-up signals AI drug design is moving faster than venture timelines.
Why it matters
A biotech startup using AI to design protein therapeutics is raising incremental capital mid-seed due to execution velocity — a signal that AI-driven drug discovery is compressing timelines and attracting follow-on capital from believers.
The key facts
11 to know$10.5M seed top-up from existing investors
Faster-than-expected progress cited as driver
Plans to double roster of clinical-stage drug candidates
Focus area: immunology
Team expansion underway
AI-designed multi-target protein therapeutics (domain: drug design)
Accipiter Bio raised $10.5M additional seed funding from existing investors
Funding driven by faster-than-expected progress on AI-designed multi-target protein therapeutics
Plans to expand team and double clinical-stage drug candidate roster
Focus on immunology applications
Seattle-based biotech startup
Go to the source
GeekWiregeekwire.com
Publisher excerpt: Seattle biotech startup Accipiter Bio has raised an additional $10.5 million from existing investors to accelerate its work on AI-designed, multi-target protein therapeutics. Fueled by faster-than-expected progress, the company plans to use the new capital to expand its team and double its roster…